101. LRRK2 regulates synaptogenesis and dopamine receptor activation through modulation of PKA activity.
- Author
-
Parisiadou L, Yu J, Sgobio C, Xie C, Liu G, Sun L, Gu XL, Lin X, Crowley NA, Lovinger DM, and Cai H
- Subjects
- Animals, Corpus Striatum pathology, Cyclic AMP-Dependent Protein Kinase RIIbeta Subunit biosynthesis, Dendritic Spines pathology, Leucine-Rich Repeat Serine-Threonine Protein Kinase-2, Mice, Mice, Knockout, Mice, Transgenic, Protein Serine-Threonine Kinases genetics, Receptors, Dopamine D1 agonists, Synapses pathology, Up-Regulation genetics, Corpus Striatum metabolism, Cyclic AMP-Dependent Protein Kinase RIIbeta Subunit metabolism, Dendritic Spines metabolism, Protein Serine-Threonine Kinases physiology, Receptors, Dopamine D1 metabolism, Synapses metabolism
- Abstract
Leucine-rich repeat kinase 2 (LRRK2) is enriched in the striatal projection neurons (SPNs). We found that LRRK2 negatively regulates protein kinase A (PKA) activity in the SPNs during synaptogenesis and in response to dopamine receptor Drd1 activation. LRRK2 interacted with PKA regulatory subunit IIβ (PKARIIβ). A lack of LRRK2 promoted the synaptic translocation of PKA and increased PKA-mediated phosphorylation of actin-disassembling enzyme cofilin and glutamate receptor GluR1, resulting in abnormal synaptogenesis and transmission in the developing SPNs. Furthermore, PKA-dependent phosphorylation of GluR1 was also aberrantly enhanced in the striatum of young and aged Lrrk2(-/-) mice after treatment with a Drd1 agonist. Notably, a Parkinson's disease-related Lrrk2 R1441C missense mutation that impaired the interaction of LRRK2 with PKARIIβ also induced excessive PKA activity in the SPNs. Our findings reveal a previously unknown regulatory role for LRRK2 in PKA signaling and suggest a pathogenic mechanism of SPN dysfunction in Parkinson's disease.
- Published
- 2014
- Full Text
- View/download PDF